Different coexisting gynecological and endometrial pathologies in postmenopausal breast cancer patients treated with tamoxifen

Gynecologic and Obstetric Investigation

Volumn 46, Issue 2, 1998, Pages 123-129

  Cohen, Ilan ^a   Beyth, Yoram ^a   Bernheim, Joelle ^a   Shapira, Jeremiah ^a   Cordoba, Mario ^a   Aviram, Rami ^a   Figer, Arie ^b   Yigael, Dror ^a   Altaras, Marco M ^a  

^a MEIR MEDICAL CENTER   (Israel)

^b Beilinson Medical Center   (Israel)

Author keywords

Gynecological pathologies; Menopause; Tamoxifen

Indexed keywords

TAMOXIFEN;

ABDOMINAL HYSTERECTOMY; ADULT; AGED; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EXPOSURE; ENDOMETRIUM; FEMALE; GYNECOLOGIC DISEASE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MYOMETRIUM; OVARY; POSTMENOPAUSE; PRIORITY JOURNAL; SALPINGOOOPHORECTOMY; STATISTICAL ANALYSIS;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; INCIDENCE; NEOPLASMS, MULTIPLE PRIMARY; NEOPLASMS, SECOND PRIMARY; POSTMENOPAUSE; TAMOXIFEN;

EID: 0031713614     PISSN: 03787346     EISSN: None     Source Type: Journal    
DOI: 10.1159/000010015     Document Type: Article

References (37)

1. Early reast Cancer Trialists' Collaborative Group: Systmic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 1992;339:1-15, 71-85.
2. Neven P, De Muylder X, Van Belle Y, Vanderick G, De Muylder E: Tamoxifen and the uterus and endometrium. Lancet 1989;ii:375.
3. De Muylder X, Neven P, DeSomer M: Endometrial lesions in patients undergoing tamoxifen therapy. Int J Gynecol Oncol 1991;36:127-129.
4. Cohen I, Rosen DJD, Shapira J, Cordoba M, Gilboa S, Altaras MM, Yigael D, Beyth Y: Endometrial changes in postmenopausal women treated with tamoxifen for breast cancer. Br J Obstet Gynaecol 1993;100:567-570.
5. Lahti E, Blanco G, Kauppila A, Apaja-Sarkkinen M, Taskinen PJ, Laatikainen T: Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstet Gynecol 1993;81:660-664.
6. Cohen I, Rosen DJD, Shapira J, Cordoba M, Gilboa S, Altaras MM, Beyth Y: Endometrial changes with tamoxifen: Comparison between tamoxifen-treated and nontreated asymptomatic postmenopausal breast cancer patients. Gynecol Oncol 1994;52:158-190.
7. Cohen I, Tepper R, Rosen DJD, Shapira J, Cordoba M, Altaras MM, Yigael D, Beyth Y: Continuous tamoxifen treatment in asymptomatic, postmenopausal treated breast cancer patients does not cause aggravation of endometrial pathologies. Gynecol Oncol 1994;55:138-143.
8. Ugwumadu AH, Bower D, Kin-Hoi P: Tamoxifen induced adenomyosis and adenomyomatous endometrial polyp. Br J Obstet Gynaecol 1993;100:386-392.
9. Kedar RP, Bourne TH, Powles TJ, Collins WP, Ashley SE, Cosgrove DO, Campble S: Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomized breast cancer prevention trial. Lancet 1994;343:1318-1321.
10. Cohen I, Altaras MM, Shapira J, Tepper R, Rosen DJD, Cordoba M, Zalel Y, Figer A, Yigael D, Beyth Y: Time-dependent effect of tamoxifen therapy on endometrial and cervical pathologies in asymptomatic postmenopausal breast cancer patients. Int J Gynecol Pathol 1996;15:152-157.
11. Ismail SM: Pathology of endometrium treated with tamoxifen. J Clin Pathol 1994;47:827-833.
12. Nuovo MA, Nuovo GJ, McCaffrey RM, Levine RU, Barren B, Winkler B: Endometrial polyps in postmenopausal patients receiving tamoxifen. Int J Gynecol Pathol 1989;8:125-131.
13. Corley D, Rome J, Curtis MT, Hogan WM, Noumoff JC, Livolsi VA: Postmenopausal bleeding from unusual endometrial polyps in women on chronic tamoxifen therapy. Obstet Gynecol 1992;79:111-116.
14. Hardell L: Tamoxifen as a risk factor for carcinoma of corpus uteri. Lancet 1989;ii:563.
15. Fornander T, Cedermak B, Mattson A, Skoog L, Theve T, Askergen J, Rutquist LE, Glas U, Silfverswrad C, Somell A, Wilkins N, Hjalmar ML: Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancers. Lancet 1989;ii:117-120.
16. Andersson M, Storm HH, Mouridsen HT: Incidence of new primary cancers after adjuvant tamoxifen and radiotherapy for early breast cancer. J Natl Cancer Inst 1991;83:1013-1017.
17. Sagna RA, Dottino PR, Deligdisch L, Cohen CJ: Tamoxifen and endometrial cancer. Mt Sinai J Med 1992;59:416-418.
18. Magriples U, Naftolin F, Schwartz PE, Carcangiu ML: High grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol 1993;11:485-490.
19. Seoud MA-F, Johnson J, Weed JC: Gynecologic tumors in tamoxifen-treated women with breast cancer. Obstet Gynecol 1993;82:165-169.
20. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham L, Cronin WM: Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994;86:527-537.
21. van Leeuwen FE, Benraadt J, Coebergh JWW, Kiemeney LA, Gimbrere CH, Otter R, Schouten LJ, Damhuis RAM, Bontenbal M, Diepenhorst FW, van Tinteren H: Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 1994;343:448-452.
22. Barakat RF, Wang G, Curtin J, Vlamis V, Hoskins WJ: Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features. Gynecol Oncol 1994;55:164-168.
23. Rutquist LE, Johanson H, Signomaklo T, Johanson U, Fornander T, Wilking N: Adjuvant tamoxifen therapy for early stage breast cancer and second primary cancer. J Natl Cancer Inst 1995;87:645-651.
24. Cook LS, Weiss NS, Schwartz SM, White E, McKnight B, Moore DE, Daling JR: Population-based study of tamoxifen therapy and subsequent ovarian, endometrial and breast cancer. J Natl Cancer Inst 1995;87:1359-1364.
25. Bocklage T, Lee KR, Belinson JL: Uterine mullerian adenosarcoma following adenomyoma in a woman on tamoxifen therapy. Gynecol Oncol 1992;44:104-109.
26. Altaras MM, Aviram R, Cohen I, Cordoba M, Yarkoni S, Beyth Y: Role of prolonged Stimulation of tamoxifen therapy in the etiology of endometrial sarcomas. Gynecol Oncol 1993; 49:255-258.
27. Clarke MR: Uterine malignant mixed mullerian tumor in a patient on long-term tamoxifen therapy for breast cancer: Case report. Gynecol Oncol 1993;51:411-415.
28. Steward HJ, Knight GM: Tamoxifen and the uterus and endometrium. Lancet 1989;i:375-376.
29. Dilts PV, Hopkins MP, Chang AE, Cody RL: Rapid growth of leiomyoma in patient receiving tamoxifen. Am J Obstet Gynecol 1992;166: 167-168.
30. Cohen I, Beyth Y, Tepper R, Figer A, Shapira J, Cordoba M, Yigael D, Altaras MM: Adenomyosis in postmenopausal breast cancer patients treated with tamoxifen: A new entity? Gynecol Oncol 1995;58:86-91.
31. Ford MRW, Turner MJ, Wood C, Sautter WP: Endometriosis developing during tamoxifen therapy. Am J Obstet Gynecol 1988;158:1119.
32. Cohen I, Beyth Y, Tepper R, Shapira J, Zalel Y, Figer A, Cordoba M, Dror Y, Altaras MM: Ovarian tumors in postmenopausal breast cancer patients treated with tamoxifen. Gynecol Oncol 1996;60:54-58.
33. Gorodeski GI, Beery R, Lunenfeld B, Geier A: Tamoxifen increases plasma estrogen binding equivalents and has an estradiol agonistic effect on historically normal premenopausal and postmenopausal endometrium. Fertil Steril 1992;57:320-327.
34. Anzai Y, Halink CF, Kuramoto H, Gurpride E: Stimulatory effects of U-hydroxytamoxifen on proliferation of human endometrial adenocarcinoma cells (Ishikawa line). Cancer Res 1989; 49:2362-2365.
35. Gottardis MM, Robinson SP, Satyaswaroop PG, Jordan VC: Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res 1988;118:812-815.
36. Vercellini P, Parazzini F, Panazza S: Adenomyosis at hysterectomy: A study on frequency distribution and patient characteristics. Hum Reprod 1995;10:1160-1162.
37. Kiang DT, Kennedy BJ: Factors affecting estrogen receptors in breast cancer. Cancer 1977; 40:1571-1576.